Director, COSMOS Pharmaceutical Corporation
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) dividends retained by asset-management companies (less about 20% corporate tax), and proceeds from share sales (the drop in shares from the previous year × share price, less 20.315% tax, or about 30% for asset-management companies), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| COSMOS Pharmaceutical Corporation 3349 · FY ending May 2026 · Director |
Own name | 2,102,000 | — | ¥6,024 | ¥12.7B | ¥172M |
| Year | Net worth | Pay | Dividends | Total income | Taxes (est.) | After tax (est.) | Share sales (after tax) |
|---|---|---|---|---|---|---|---|
| 2026 | ¥12.7B | — | ¥172M | ¥172M | ¥35.0M | ¥137M | — |
| 2025 | ¥18.6B | — | ¥147M | ¥147M | ¥29.9M | ¥117M | — |
Grouped by the calendar year of each company's fiscal year-end. Years in which the person was not among the top 10 shareholders of a company exclude that company.